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Clinical background
Chronic nitroglycerin (GTN) anti-ischemic therapy induces
side effects such as nitrate tolerance and endothelial dys-
function. Both phenomena could be based on a desensitiza-
tion/oxidation of the soluble guanylyl cyclase (sGC).
Therefore, the present study aims at investigating the
effects of the therapy with the sGC activator BAY 60-2770
and the sGC stimulator BAY 41-8543 on side effects
induced by chronic nitroglycerin treatment. Male Wistar
rats were treated with nitroglycerin (100 mg/kg/d
for 3.5 days, s.c. in ethanol) and BAY 60-2 770 (0.5 or
2.5 mg/kg/d) or BAY 41-8543 (1 and 5 mg/kg/d) for 6 days.
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Figure 1 Aortic DHE fluorescence Effects of sGC activator BAY 60-2770 and sGC stimulator BAY 41-8543 in vivo treatment on oxidative stress
parameters in tolerant rats. Quantification of vascular ROS formation in aortic cryo-sections was assessed by fluorescent microtopography using
the superoxide-sensitive dye DHE (1 µM). The data are the means ± SEM from 3-4 animals/group. *, p<0.05 vs. control; #, p<0.05 vs. GTN;
$, p<0.05 vs. BAY 60-2770; ^, p<0.05 vs. low dose treatment.
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Conclusion
Therapy with BAY 60-2770 but not with BAY 41-8543
improved nitroglycerin-triggered endothelial dysfunction
and nitrate tolerance, corrected the decrease in aortic
nitric oxide levels, improved the cGMP dependent acti-
vation of protein kinase I in aortic tissue and reduced
vascular, cardiac and whole blood oxidative stress (fluor-
escence and chemiluminescence assays; 3-nitrotyrosine
staining). In contrast to BAY 41-8543, the vasodilator
potency of BAY 60-2770 was not impaired in isolated
aortic ring segments from nitrate tolerant rats. sGC acti-
vator therapy improves partially the adverse effects of
nitroglycerin therapy whereas sGC stimulation has only
minor beneficial effects pointing to a nitroglycerin-
dependent sGC oxidation/inactivation mechanism con-
tributing to nitrate tolerance.
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Figure 2 Cardiac 3NT staining
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